Prognostic value of P-selectin and sST2 in patients with multiple myeloma

Autor: M. O. Panasenko, B. B. Samura, S. Ya. Dotsenko
Jazyk: English<br />Russian<br />Ukrainian
Rok vydání: 2022
Předmět:
Zdroj: Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 15, Iss 3, Pp 307-312 (2022)
Druh dokumentu: article
ISSN: 2409-2932
2306-8094
DOI: 10.14739/2409-2932.2022.3.266453
Popis: Cardiac involvement is one of the most important prognostic markers in multiple myeloma. However, prognostic value of novel biomarkers, such as soluble suppression of tumorigenicity 2 (sST2), P-selectin is unknown in multiple myeloma. The aim of the work was to investigate the additive predictive effects of novel biomarkers P-selectin and sST2 for cardiovascular events of multiple myeloma patients. Materials and methods. Levels of P-selectin and sST2 were after anticancer treatment in a total of 67 multiple myeloma patients. The median follow-up duration of the censored cases was 14.0 (11.4–19.1) months. A total of 4 deaths occurred during the follow-up period. ELISA method for measurements of circulating level of P-selectin and sST2 was used. Results. During follow-up, 36 cardiovascular events and 2 deaths unrelated to cardiovascular events were recorded in 18 (26.9 %) patients. During the study, patients were hospitalized 10 times due to cardiovascular disease. At baseline patients with MM and cardiovascular events which appeared during the observation period had higher levels of P-selectin (P < 0.01), sST2 (P = 0,018), compared to patients without cardiovascular events. Two novel biomarkers, P-selectin and sST2 showed satisfactory predictive performances for one-year cardiovascular events from ROC analysis. Best cut-off values for predicting one-year cardiovascular events were selected (for sST2 – 31.05 ng/ml, with a sensitivity of 71.5 % and a specificity of 89.8 %; for P-selectin – 54.21 ng/ml, with a sensitivity of 69.6 % and a specificity of 86.2 %). The combination of biomarkers had better prognostic properties compared to P-selectin. Conclusions. In patients with confirmed multiple myeloma, the biomarkers P-selectin and sST2 showed significant prognostic properties in the occurrence of cardiovascular events during 1 year of follow-up.
Databáze: Directory of Open Access Journals
Externí odkaz: